| XLS |
|
|
|
|
||
|
€ million |
Q1 – 2014 |
Q1 – 2013 |
||
|
||||
|
Profit after tax |
327.4 |
269.0 |
||
|
Depreciation/amortization/impairment losses/reversals of impairments |
301.9 |
354.4 |
||
|
Changes in inventories |
–38.0 |
–21.0 |
||
|
Changes in trade accounts receivable |
–20.4 |
–134.2 |
||
|
Changes in trade accounts payable |
–46.2 |
–39.5 |
||
|
Changes in provisions |
–47.0 |
22.7 |
||
|
Changes in other assets and liabilities |
–74.3 |
71.9 |
||
|
Neutralization of gain/loss on disposals of assets |
–0.3 |
–4.4 |
||
|
Other non-cash income and expenses |
5.5 |
–3.1 |
||
|
Net cash flows from operating activities |
408.7 |
515.7 |
||
|
|
|
|
||
|
Investments in intangible assets |
–7.9 |
–28.9 |
||
|
Investments in property, plant and equipment |
–57.4 |
–37.5 |
||
|
Proceeds from the sale of property, plant and equipment1 |
0.8 |
5.0 |
||
|
Investments in financial assets1 |
–165.7 |
–318.0 |
||
|
Acquisitions1 |
– |
–15.1 |
||
|
Disposal of investments1 |
1,329.8 |
70.1 |
||
|
Net cash flows from investing activities |
1,099.7 |
–324.3 |
||
|
|
|
|
||
|
Dividend payments |
–2.6 |
–1.9 |
||
|
Repayment of financial liabilities due to E. Merck KG1 |
–11.0 |
–46.2 |
||
|
Changes in current and non-current financial liabilities |
20.7 |
–58.6 |
||
|
Net cash flows from financing activities |
7.1 |
–106.7 |
||
|
|
|
|
||
|
Changes in cash and cash equivalents |
1,515.5 |
84.7 |
||
|
Changes in cash and cash equivalents due to currency translation |
–0.9 |
–0.4 |
||
|
Cash and cash equivalents as of January 1 |
980.8 |
729.7 |
||
|
Cash and cash equivalents as of March 31 |
2,495.4 |
814.0 |
||
|
Plus cash and cash equivalents included in assets held for sale |
– |
– |
||
|
Cash and cash equivalents as of March 31 (consolidated balance sheet) |
2,495.4 |
814.0 |
||